From Financial Modeling Prep: 2025-04-16 16:09:00

Abbott Laboratories beat first-quarter earnings expectations, reporting $1.09 per share compared to analysts’ $1.07. Revenue reached $10.36 billion, just under the forecasted $10.4 billion. The diabetes care segment showed strong growth, with a 16% revenue increase to $1.83 billion, driving total medical device sales to $4.9 billion.

However, Abbott’s diagnostics division saw a 7.2% revenue decline to $2.05 billion, below estimates of $2.19 billion. Despite this, the company reaffirmed its full-year 2025 guidance, expecting organic sales growth between 7.5% and 8.5%, with adjusted EPS in the range of $5.05 to $5.25. Q2 adjusted earnings are forecasted between $1.23 and $1.27 per share.



Read more at Financial Modeling Prep:: Abbott Beats Q1 Expectations & Reaffirms 2025 Outl…